A Randomized, Multicenter,
Phase 3 Study Comparing
Carfilzomib, Lenalidomide, and
Dexamethasone (CRd) vs
Lenalidomide and
...
Background
A Randomized, Multicenter,
Phase 3 Study Comparing
Carfilzomib, Lenalidomide, and
Dexamethasone (CRd) vs
Lenalidomide and
...
To compare progression-free survival in subjects with
relapsed multiple myeloma who are receiving CRd vs
subjects receivin...
Phase 3, randomized, open-label, multicenter study
comparing two treatment regimens for subjects with
relapsed multiple my...
Subjects will receive the treatment determined by
randomization in 28-day cycles until disease
progression or unacceptable...
Symptomatic multiple myeloma with measurable disease, as defined by
one or both of the following (assessed within 14 days ...
• Eastern Cooperative Oncology Group performance status 0–2
• Adequate hepatic function, with serum ALT ≤ 3.5 times the up...
• Written informed consent in accordance with federal, local, and
institutional guidelines
• Females of childbearing poten...
1. If previously treated with bortezomib (alone or in combination),
progression during treatment
2. If previously treated ...
9. Radiotherapy to multiple sites or immunotherapy/antibody therapy
within 28 days prior to randomization; localized radio...
18. Other malignancy within the past 3 years with the exception of
a) adequately treated basal cell carcinoma, squamous ce...
Rd Arm
Cycles 1 and higher (28 days each)
 Dexamethasone 40 mg PO or IV on Days 1, 8, 15, 22
 Lenalidomide 25 mg PO on D...
Rd Arm
Cycles 1 and higher (28 days each)
 Dexamethasone 40 mg PO or IV on Days 1, 8, 15, 22
 Lenalidomide 25 mg PO on D...
Primary : Progression-free survival (PFS)
Endpoints
Secondary : Overall survival
 Overall response rate: stringent comple...
Discussion
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and ...
Upcoming SlideShare
Loading in …5
×

A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma

623 views
458 views

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
623
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
11
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma

  1. 1. A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma Michael Wang, M.D. Associate Professor Department of Lymphoma and Myeloma M. D. Anderson Cancer Center
  2. 2. Background
  3. 3. A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma Michael Wang, M.D. Associate Professor Department of Lymphoma and Myeloma M. D. Anderson Cancer Center
  4. 4. To compare progression-free survival in subjects with relapsed multiple myeloma who are receiving CRd vs subjects receiving Rd alone in a randomized multicenter setting. PRIMARY OBJECTIVES
  5. 5. Phase 3, randomized, open-label, multicenter study comparing two treatment regimens for subjects with relapsed multiple myeloma. Subjects will be randomized in a 1:1 ratio to receive either the control Rd or CRd. Randomization will be stratified by β2 microglobulin levels (< vs ≥ 2.5 mg/L), prior bortezomib (no vs yes), and prior lenalidomide (no vs yes). Estimated sample size is 700 subjects and will take place at approximately 200 centers. Primary endpoint is progression-free survival. STUDY DESIGN
  6. 6. Subjects will receive the treatment determined by randomization in 28-day cycles until disease progression or unacceptable toxicity. Subjects will be followed for 30 additional days after completion or early discontinuation of treatment for safety follow-up. Long-term follow-up for disease status and survival will continue until the subject has withdrawn consent for further participation, is lost to follow-up, has died, or the Sponsor makes a decision to close the study. STUDY DESIGN Continued
  7. 7. Symptomatic multiple myeloma with measurable disease, as defined by one or both of the following (assessed within 14 days prior to randomization): • Serum M-protein ≥ 0.5 g/dL • Urine Bence-Jones protein ≥ 200 mg/24 hours Prior treatment with at least one, but no more than three, regimens for multiple myeloma Documented relapse or progressive disease on or after any regimen (subjects refractory to the most recent line of therapy are eligible) Achieved a response to at least one prior regimen (defined as ≥ 25% decrease in M-protein Age ≥ 18 years and Life expectancy ≥ 3 months Eligibility Criteria - Inclusion
  8. 8. • Eastern Cooperative Oncology Group performance status 0–2 • Adequate hepatic function, with serum ALT ≤ 3.5 times the upper limit of normal and serum direct bilirubin ≤ 2 mg/dL (34 μmol/L) within 14 days prior to randomization • Absolute neutrophil count ≥ 1.0 × 109/L within 14 days prior to randomization •Hemoglobin ≥ 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be receiving red blood cell transfusions in accordance with institutional guidelines) • Platelet count ≥ 50 × 109/L (≥ 30 × 109/L if myeloma involvement in the bone marrow is > 50%) within 14 days prior to randomization • Creatinine clearance (CrCl) ≥ 50 mL/minute (either measured or calculated using a standard formula such as Cockcroft and Gault) within 7 days prior to randomization Eligibility Criteria - Inclusion
  9. 9. • Written informed consent in accordance with federal, local, and institutional guidelines • Females of childbearing potential must agree to ongoing pregnancy testing and to practice contraception as outlined • Male subjects must agree to practice contraception as outlined Eligibility Criteria - Inclusion
  10. 10. 1. If previously treated with bortezomib (alone or in combination), progression during treatment 2. If previously treated with a lenalidomide and dexamethasone (len/dex) combination: • Progression during the first 3 months of initiating treatment • Any progression during treatment if the len/dex regimen was the subject’s most recent line of therapy 3. Discontinuation of previous lenalidomide or dexamethasone due to intolerance; subjects who are intolerant to bortezomib are not excluded 4. Prior carfilzomib treatment 5. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) 6. Waldenström’s macroglobulinemia or IgM myeloma 7. Plasma cell leukemia (> 2.0 × 109/L circulating plasma cells by standard differential) 8. Chemotherapy (approved or investigational) within 3 weeks prior to randomization or antibody therapy within 6 weeks prior to randomization Eligibility Criteria - Exclusion
  11. 11. 9. Radiotherapy to multiple sites or immunotherapy/antibody therapy within 28 days prior to randomization; localized radiotherapy to a single site within 7 days prior to randomization 10. Corticosteroid therapy at dose equivalent to dexamethasone > 4 mg/day within 21 days prior to randomization 11. Pregnant or lactating females 12. Major surgery within 21 days prior to randomization 13. Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization 14. Known human immunodeficiency virus infection 15. Active hepatitis B or C infection 16. Myocardial infarction within 4 months prior to randomization, NYHA Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker 17. Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to randomization Eligibility Criteria - Exclusion
  12. 12. 18. Other malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas 19. Significant neuropathy (Grades 3–4, or Grade 2 with pain) within 14 days prior to randomization 20. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib) 21. Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment 22. Ongoing graft-vs-host disease 23. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization 24. Any other clinically significant medical disease or condition that, in the Investigator’s opinion, may interfere with protocol adherence or a subject’s ability to give informed consent Eligibility Criteria - Exclusion
  13. 13. Rd Arm Cycles 1 and higher (28 days each)  Dexamethasone 40 mg PO or IV on Days 1, 8, 15, 22  Lenalidomide 25 mg PO on Days 1–21 CRd Arm Cycles 1 through 12 (28 days each)  Dexamethasone 40 mg PO or IV on Days 1, 8, 15, 22  Carfilzomib 20 mg/m2 IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 IV on Days 8, 9, 15, 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, 16 of Cycles 2 through Cycle 12  Lenalidomide 25 mg PO on Days 1–21 Cycles 13 through 18 (28 days each)  Dexamethasone 40 mg PO or IV on Days 1, 8, 15, 22  Carfilzomib 27 mg/m2 IV on Days 1, 2, 15, 16  Lenalidomide 25 mg PO on Days 1–21 Cycles 19 and higher (28 days each)  Dexamethasone 40 mg PO or IV on Days 1, 8, 15, 22  Lenalidomide 25 mg PO on Days 1–21 Study Treatment
  14. 14. Rd Arm Cycles 1 and higher (28 days each)  Dexamethasone 40 mg PO or IV on Days 1, 8, 15, 22  Lenalidomide 25 mg PO on Days 1–21 CRd Arm Cycles 1 through 12 (28 days each)  Dexamethasone 40 mg PO or IV on Days 1, 8, 15, 22  Carfilzomib 20 mg/m2 IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m2 IV on Days 8, 9, 15, 16 of Cycle 1 and continuing on Days 1, 2, 8, 9, 15, 16 of Cycles 2 through Cycle 12  Lenalidomide 25 mg PO on Days 1–21 Cycles 13 through 18 (28 days each)  Dexamethasone 40 mg PO or IV on Days 1, 8, 15, 22  Carfilzomib 27 mg/m2 IV on Days 1, 2, 15, 16  Lenalidomide 25 mg PO on Days 1–21 Cycles 19 and higher (28 days each)  Dexamethasone 40 mg PO or IV on Days 1, 8, 15, 22  Lenalidomide 25 mg PO on Days 1–21 Study Treatment
  15. 15. Primary : Progression-free survival (PFS) Endpoints Secondary : Overall survival  Overall response rate: stringent complete response + complete response + very good partial response + partial response  Disease control rate: overall responses + stable disease lasting at least 8 weeks  Duration of response  Safety  Time to progression (exploratory)  Time to next treatment (exploratory)
  16. 16. Discussion

×